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Abstract
Background: Previous study showed that dsP53-285 has the capacity to induce tumor suppressor gene p53
expression by targeting promoter in non-human primates’ cells. And it is well known that TP53 gene is frequently
mutant or inactivated in human bladder cancer. Hereby, whether this small RNA can activate the expression of
wild-type p53 and inhibit human bladder cancer cells remains to be elucidated.
Methods: Oligonucleotide and lentivirus were used to overexpress dsP53-285 and dsControl. Real-time PCR and
western blot were used to detect genes’ mRNA and protein expression, respectively. Cell proliferation assay, colony
formation, flow cytometry, transwell assay and wound healing assay were performed to determine the effects on
bladder cancer cells proliferation and migration/invasion in vitro. Animal models were carried out to analyze the
effects on cells growth and metastasis in vivo.
Results: Transfection of dsP53-285 into human bladder cancer cell lines T24 and EJ readily activate wild-type p53
expression by targeting promoter. Moreover, dsP53-285 exhibited robust capacity to inhibit cells proliferation and
colony formation, induce cells G0/G1 arrest, suppress migration and invasion. Besides, the Cyclin-CDK genes (Cyclin
D1 and CDK4/6) were down-regulated and the EMT-associated genes (E-cadherin, β-catenin, ZEB1 and Vimentin)
were also expressed inversely after dsP53-285 treatment. In addition, dsP53-285 could also significantly suppress the
growth of bladder cancer xenografts and metastasis in nude mice. Most importantly, the anti-tumor effects
mediated by dsP53-285 were mainly achieved by manipulating wild-type p53 expression.
Conclusion: Our findings indicate that the dsP53-285 can upregulate wild-type p53 expression in human bladder
cancer cells through RNA activation, and suppresses cells proliferation and metastasis in vitro and in vivo.
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Background
Bladder cancer is a major cause of morbidity and mor-
tality worldwide, and with an expected 74,000 newly
diagnosed cases and 16,000 deaths in United States in
2015 [1]. Risk factors, such as genetic and molecular
abnormalities, chemical or environmental exposures,
and chronic irritation, may contribute to the develop-
ment of bladder cancer [2]. At diagnosis, more than
90 % of bladder cancer patients presents transitional cell
carcinoma [3]. Approximately 75 % of newly diagnosed
bladder cancer cases appear as non-muscular invasive
tumors, they have a high rate of recurrence and progres-
sion despite local therapy. The remaining 25 % of newly
diagnosed cases are muscle invasive and need either
radical surgery or radiotherapy but often still have poor
prognosis despite systemic treatment [4, 5].
As an essential tumor suppressor, wild-type p53 is often
mutated or inactivated in bladder cancer, especially in
muscular invasive tumors [6, 7]. Moreover, independent
of tumor grade, stage and lymph-node status, the express-
ing level of p53 has been implicated as an important pre-
dictor of recurrence, progression and survival of patients
with bladder cancer [8]. Additionally, alterations of the
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wild-type p53 play a crucial role in the carcinogenesis of
bladder urothelial cancers [9]. Therefore, gain-of-function
manipulation of wild-type p53 would be an ideal target for
inhibiting bladder cancer cells.
RNA activation (RNAa) is a recently discovered mech-
anism of gene activation at transcriptional level triggered
by small double-stranded RNAs (dsRNAs), and this
dsRNAs are termed as small activating RNAs (saRNAs)
[10]. What’s more, this novel gene positive regulation
mechanism is conserved in at least mammalian cells
[11]. A previous study has shown that a candidate
dsRNA (dsP53-285) targeting sequence position -285
relative to the transcription start sites (TSS) in the hu-
man p53 promoter significantly induced p53 expression
in cells of non-human primates [12]. As such, reactiva-
tion of p53 through RNAa may offer a promising new
therapeutic strategy for bladder cancer.
However, whether dsP53-285 can induce wild-type
p53 expression in human bladder cancer cells remains
unknown. In the present study, we transfected dsP53-
285 into bladder cancer cell lines T24 and EJ for 72 h,
and examined the wild-type p53 expression. Our results
showed that dsP53-285 had potent ability to inhibit
bladder cancer cells proliferation and metastasis by
modulating wild-type p53 expression.
Methods
dsRNAs and recombinant Lentivirus
All the RNA duplexes used in present study which pos-
sesses 2-nucleotide 3’ overhangs were chemically synthe-
sized by RiboBio Co., Ltd. (Guangzhou, China). A small
interfering RNA (siP53) was used to silence p53 expres-
sion and a dsControl which lacks significant homology
to all known human sequences was used as a negative
control [10, 13]. Lenti-dsP53-285 and Lenti-dsControl
were purchased from GenePharma (Shanghai, China).
The sequences of all the custom dsRNAs are listed in
Additional file 1: Table S1.
Cell culture, transfection with dsRNAs and infection with
Lentivirus
The human bladder cancer cell lines T24 and EJ (ATCC)
were cultured in RPMI 1640 medium (Hyclone, USA)
supplemented with 10 % fetal bovine serum (Gibco, USA)
in a humidified atmosphere with 5 % CO2 at 37 °C. The
day before transfection, cells were trypsinized and plated
to a new 6-well plate with growth medium at a density of
50-60 % without antibiotics. All dsRNAs were transfected
at a final concentration of 50 nM by using Lipofectamine
RNAiMax (Invitrogen, USA) according to the manufac-
turer’s instructions. Besides, dsRNA was replaced by
MEM in mock transfection.
The day before infection, 3-5 × 103 cells were seeded in
a 96-well plate with 100 μL culture medium, to ensure
cells are at a density of 40-60 % in each well when infec-
tion. EJ cells were infected with Lenti-dsP53-285 or Lenti-
dsControl according to the manufacturer’s protocol with
modification. Culture medium was substituted 24 h later.
Fluorescence expression was observed at 72-96 h after in-
fection. Then cells were harvested and reseeded into new
plates for further experiments.
RNA isolation and quantitative real-time PCR
Total cellular RNA was extracted from bladder cancer
cells by using TRIzol reagent (Invitrogen, USA) accord-
ing to the manufacturer’s protocol. After quantified by a
Nano Drop ND-1000 spectrophotometer, 500 ng RNA
was reversely transcribed into cDNA according to the
instructions provided by Takara reverse transcription kit
(Takara, China). The resulting cDNA was amplified by
SYBR Premix Ex Taq II (Takara, China) conducted on
the Mx3000P instrument (Stratagene, USA). All the
primers included in this study were provided by Invitro-
gen (Shanghai, China) and listed in Additional file 1:
Table S2. The relative expression of target genes’ mRNA
was calculated with the 2-ΔΔCt method. GAPDH was
used as internal control. All experiments were done in
triplicate.
Protein extraction and Western blotting analysis
All the cells were gathered and total proteins were ex-
tracted using RIPA lysis buffer supplemented with prote-
ase inhibitor Cocktail (Roche, Switzerland). Protein
concentrations were calculated by using BCA protein
assay kit (Beyotime, China). Equivalent amounts of pro-
tein samples (50 μg) were separated by 10 % sodium do-
decyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and then transferred to polyvinylidene fluoride
(PVDF) membranes. Nonspecific binding was blocked
by incubating the PVDF membranes with 5 % bovine
serum albumin (BSA) (Sigma-Aldrich, USA) for 2 h at
room temperature. The membrane was then incubated
with primary antibodies included p53 (1/1000) (Cell
Signaling Technology, USA), p21 (1/2000) (Cell Signaling
Technology, USA), Cyclin D1 (1/2000) (Affinity, USA),
CDK4 (1/1000) (Affinity, USA), CDK6 (1/2000) (Affinity,
USA), E-cadherin (1/1000) (BD Biosciences), β-catenin
(1/500) (Boster, China), Vimentin (1/500) (Boster, China),
ZEB1 (1/1000) (Cell Signaling Technology, USA), GAPDH
(1/500) (Boster, China) and α-tubulin (1/500) (Boster,
China) at 4 °C overnight. After several washes, the mem-
branes were incubated with corresponding secondary
antibody and detected by enhanced chemiluminescence
(ECL) assay kit (Millipore, USA).
Cell proliferation assay
Cell proliferation was detected using the CellTiter 96®
AQueous One Solution Cell Proliferation Assay kit
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(Promega, USA) according to the manufacturer’s proto-
col. Briefly, cells were transfected with indicated dsRNAs
in a 6-well plate. The cells were trypsinized and seeded
at 1000 cells/well into a new 96-well plate 24 h later.
Cell growth was measured at daily interval from the next
day to the fifth day. At each time point, 20 μl of CellTi-
ter 96® AQueous One Solution was added to each well
and incubated for 2 h at 37 °C. Absorbance was mea-
sured on a microplate reader (Bio-Rad, USA) at 490 nm.
Clonogenic survival assay
T24 and EJ cells were harvested 24 h after transfection of
indicated dsRNAs. 1000 cells were reseeded in each new
6-well plate with complete medium for 10 days. The
medium was replaced every 3 days to maintain the cells
growth. The colonies were then fixed and stained with
0.5 % crystal violet (Sigma, USA) for 30 min at room
temperature. The colony formation rate was calculated
using the following equation: colony formation rate =
number of colonies/number of seeded cells × 100 %.
Cell cycle analysis by flow cytometry
Cells were harvested 72 h after transfection and fixed with
70 % ethanol at 4 °C overnight. Then the cells were
washed and incubated with RNase A (0.1 mg/mL) for
30 min at 37 °C. Cellular DNA was stained with propi-
dium iodide (PI) (0.05 mg/mL) and analyzed on a FACSort
flow cytometer (BD Biosciences, USA). All experiments
were repeated 3 times and a total of 10,000 events were
analyzed for each sample. The data were processed by
CELL Quest software (BD Biosciences, USA).
Wound healing assay
After 72 h transfection, cells were trypsinized and
counted. Approximate 5 × 105 cells were reseeded in
each well of a new 6-well plate. With incubation over-
night, the confluent cells monolayers were scratched
with a 10 μL sterile pipette tip. Then the non-adherent
cells were washed off with sterilized PBS and serum-free
medium was added into the wells. The gap area caused
by the scratch was monitored by the inverted micro-
scope (Olympus, Japan). Three random non-overlapping
areas in each well were pictured at 0 h, 12 h and 24 h
post-scratch. Scratch width between the two linear
regions was quantitated for assessing capacity of cells
migration.
Migration and invasion assay
The 24-well Boyden chamber with 8 μm pore size poly-
carbonate membrane (Corning, USA) was used to
analyze the cell motility. For invasion assay, the mem-
brane was pre-coated with matrigel (BD Biosciences,
USA) to form a matrix barrier. 2 × 104 cells, transfected
with dsRNAs for 72 h, were seeded on the upper
chamber with serum-free medium. Medium with 10 %
serum was added to the lower chamber as a chemo-
attractant. The membranes were fixed at 24 h and
stained with 0.5 % crystal violet (Sigma, USA). After re-
moval of the non-motile cells at the top of the
membranes with cotton swabs, 5 visual fields of 200×
magnification of each membrane were randomly selected
and counted.
In vivo tumorigenicity assay and experimental lung
metastasis model
Equivalent amounts EJ cells (about 5 × 106, 200 μL)
infected with Lenti-dsP53-285 or Lenti-dsControl were
injected subcutaneously into the right back of male
BALB/c-nude mice (Hua Fukang Biological Technology
Co., Ltd, Beijing, China) at 4 weeks of age, respectively.
Tumor length and width were measured using calipers
every 4 days for 28 days. Tumor volume was calculated
using the formula: V = length × width2 × 0.5. Animals
were sacrificed 28 days after injection and tumors were
weighed.
For in vivo metastasis assay, treated cells (2 × 105) were
suspended in 100 μL of PBS and injected intravenously
via the tail vein. At 30 days later after injection, the inci-
dence and volume of metastases were estimated by im-
aging of mice for bioluminescence using the Living
Image software (Xenogen, USA). The photon emission
level was used to assess the relative tumor burden in the
mice lungs. All nude mice were manipulated and cared
according to NIH Animal Care and Use Committee
guidelines in the Experiment Animal Center of the
Tongji medical college of Huazhong University of Science
and Technology (Wuhan, China).
Statistical analysis
All data were presented as the mean ± standard devi-
ation (SD) for three independent experiments. Differ-
ences between groups were analyzed by t-tests using
SPSS version 13.0 software (SPSS Inc., Chicago, IL,
USA). P-value < 0.05 was considered to be statistically
significant.
Results
dsP53-285 activates wild-type p53 expression by target-
ing promoter
Previous study has identified that a specific dsRNA
(dsP53-285) can induce p53 expression by targeting se-
quence position -285 relative to the TSS in the p53
promoter in African green monkey (COS1) and chim-
panzee (WES) cells [12]. As human shares almost identi-
cal genome sequences with African green monkey and
chimpanzee, we speculated that the dsP53-285 may also
activate p53 expression in human bladder cancer cells.
Hereby, we transfected synthetic dsP53-285 into T24
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and EJ cells and analyzed p53 expression 72 h later. Com-
pared with mock and dsControl groups, dsP53-285 caused
a significant induction in p53 mRNA (Fig. 1a). This induc-
tion was further verified by Immunoblot (Fig. 1b).
It is well known that only wild-type p53 can positively
regulate p21 expression [14]. To determine the expres-
sion type of p53 in dsP53-285 induced T24 and EJ cells,
we further examined the downstream p21 levels. As
shown in Fig. 1c, real-time PCR revealed that dsP53-285
profoundly activated p21 levels compared to mock and
dsControl treatments. And analysis of p21 induction was
further confirmed by western blotting (Fig. 1d). More-
over, time-course experiments revealed that p53 mRNA
and protein levels were not induced until 48 h, and con-
tinued to increase at 72 h (Fig. 1e and f). Then we si-
lenced wild-type p53 expression by transfecting a small
interfering RNA siP53 into both cell lines [13]. The out-
comes showed that co-transfection of dsP53-285 and
siP53 in the two tested cells markedly abrogated the ac-
tivating effect of wild-type p53 at both mRNA and pro-
tein levels at 72 h (Additional file 2: Figure S3A and
S3B). These results suggest that dsP53-285 possesses
capacity to induce wild-type p53 expression through
RNAa in T24 and EJ cells.
dsP53-285 inhibits cells proliferation, clonegenesis and
induces cell cycle arrest mainly by upregulating wild-type
p53 expression
To investigate the effects of wild-type p53 up-regulation
mediated by dsP53-285 on bladder cancer cell lines T24
and EJ, we performed CellTiter 96® AQueous One Solution
Cell Proliferation Assay. Compared to dsControl group,
both tested cells transfected dsP53-285 exhibited progres-
sive retarded growth from the third day following transfec-
tion (Fig. 2a). Then we verified whether depletion of wild-
type p53 could affect the inhibitory function of dsP53-285
in T24 and EJ cells. As seen from Additional file 3: Figure
S1A, knockout of wild-type p53 evidently attenuated the
anti-proliferative effect mediated by dsP53-285 in both
cells. Then, the EJ cells stably expressing dsP53-285 or
dsControl were used to generate the xenograft model in
nude mice. As shown in Fig. 2g, Lenti-dsP53-285 signifi-
cantly reduced xenograft tumor growth. In addition, the
average tumor volume and weight in Lenti-dsP53-285
group was markedly smaller and lighter than the control
group at day 28 post injection, respectively (Fig. 2f and h).
In order to evaluate the cells growth mode after wild-
type p53 activated by dsP53-285, we carried out the
colony formation assay and found that dsP53-285
Fig. 1 dsP53-285 induces wild-type p53 expression by targeting promoter in human bladder cancer cells. T24 and EJ cells were transfected with
50 nM of the indicated dsRNAs or mock transfection for 72 h. GAPDH levels were detected and served as a loading control. a Expression of p53
mRNA levels was assessed by real-time PCR. b Expression of p53 protein was detected by Western blot analysis. c Expression of p21 mRNA was
detected by real-time PCR. d Expression of p21 protein was detected by Western blot analysis. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to
mock and dsControl groups. (e and f) Time-course of dsP53-285-mediated upregulation of p53 expression. Cells were subjected to real-time PCR
or western blot at the indicated time points. *P < 0.01 and **P < 0.001 compared to 0 h; #P < 0.05 and ##P < 0.01 compared to 24 h; &P < 0.05
compared to 48 h
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transfected cells formed colonies significantly fewer in
number and smaller in size (Fig. 2b). In addition, the
colony formation rates of dsP53-285 transfected cells were
remarkably lower than dsControl treatment (Fig. 2c).
Furthermore, the colony formation ability of the bladder
cancer cells was also restored after co-treatment of siP53
(Additional file 3: Figure S1B and S1C).
Nest we performed flow cytometry to measure cell
cycle distribution. In both bladder cancer cell lines,
transfection with dsP53-285 led to a significant increase
in the G0/G1 population and a corresponding decrease
in the S phase population compared with dsControl
group (Fig. 2d and e). Additionally, p53 silencing
remarkably alleviated G0/G1 cycle arrest mediated by
dsP53-285 in both cell lines (Additional file 3: Figure
S1D and S1E). These data together implied that dsP53-
285 could inhibit bladder cancer cells proliferation,
suppress colony formation and induce cell cycle G0/G1
arrest mainly via manipulating wild-type p53 expression.
dsP53-285 inhibits bladder cancer cells migration and
invasion primarily by activating wild-type p53 expression
As we know, wild-type p53 suppresses epithelial-to-
mesenchymal transition (EMT) which is a process that
plays crucial roles in the early stage of metastases, inva-
siveness and wound healing of bladder cancer [15].
Fig. 2 dsP53-285 inhibits cells proliferation, clonegenesis and induces cell cycle arrest. T24 and EJ cells were transfected with 50 nM of the
indicated dsRNAs for 72 h. Mock sample was transfected in the absence of dsRNAs. a Viable cells were measured from day 1 to 5 following
transfection using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit. Results were plotted as OD values. b Representative
photographs of colony formation assay. c Quantification of the cell colonies formation. d Representative photographs of cell cycle analysis. e
Quantification of cell cycle distribution. f Photographs of tumors excised 28 days after inoculation of stably transfected cells EJ into nude mice. g
Mean tumor volume measured by caliper on the indicated days. h Tumor weight of each nude mouse at the end of 28 days. *P < 0.05, **P < 0.01
and ***P < 0.001 compared to dsControl or Lenti-dsControl group
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Hereby, we examined the potential roles of dsP53-285
on migration and invasion capacities of bladder cancer
cells. At 72 h after transfection, cells were reseeded and
then scratches were made 24 h later. Transfection of
dsP53-285 led to retarded wound closing compared with
dsControl group from 12 h in both T24 and EJ cells
(Fig. 3a). Then the wound widths of each group were
measured and normalized to corresponding 0 h of
dsControl. The relative distances between wound edges
of dsP53-285 groups were markedly wider than those of
dsControl group in both cell lines from 12 h post-
scratch (Fig. 3b). Furthermore, compared to dsP53-285
treatment alone, siP53 co-transfected T24 and EJ cells
recovered to close the wound faster within 24 h
(Additional file 4: Figure S2A). Further quantitative
analysis of wound width indicated relative scratch widths
in co-treatment group were significantly less than
dsP53-285 transfection groups from 12 h (Additional file
4: Figure S2B).
Subsequently, the transwell assay was conducted to
further assess cells migration and invasion capability in
vitro. T24 and EJ cells transfected with dsP53-285 or
dsControl were allowed to migrate through a transwell
membrane into complete media. Compared with control,
dsP53-285 exerted a potent inhibiting effect on migra-
tion of the both cell lines (Fig. 3c and d). Likewise, inva-
sion capability of bladder cancer cells transfected dsP53-
285 was detected by Matrigel invasion chamber assay.
As expected, dsP53-285 can notably repress their inva-
sion ability compared with dsControl treatment (Fig. 3c
and d). In intravenous injection assay, bioluminescence
imaging revealed that fluorescence signal in Lenti-
dsP53-285 group was significantly weaker than lenti-
dsControl group, which mean that less metastasis is
Fig. 3 dsP53-285 suppresses bladder cancer cells migration and invasion. T24 and EJ cells were transfected with 50 nM of the indicated dsRNAs
for 72 h. a Representative wound healing images were pictured at 0, 12 and 24 h. b The relative distances between wound edges of bladder
cancer cells at 0, 12 and 24 h. c Representative photographs of transwell assay (×200). d Number of migrated and invaded cells was quantified in
5 random images from each treatment group. Results are plotted as percent (%) relative to dsControl group. e Representative bioluminescent
images of lungs of nude mice at the 30th days after intravenous injection. f Quantification analysis of fluorescence signal from captured
bioluminescence images. *P < 0.05, *P < 0.01 and ***P < 0.001 compared to dsControl or Lenti-dsControl group
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formed in lung after dsP53-285 overexpression (Fig. 3e
and f). Moreover, depletion of wild-type p53 dramatic-
ally restored cells migration in response to dsP53-285
transfection (Additional file 4: Figure S2C and S2D).
Consistent with this, cells migrated the membranes
pre-coated with matrigel were more in co-transfection
group than dsP53-285 group (Additional file 4: Figure
S2C and S2D). These results demonstrate that dsP53-
285 can suppress the migration and invasion of T24 and
EJ cells mainly by regulating wild-type p53 expression.
dsP53-285 modulates bladder cancer cells cell cycle and
EMT associated genes mainly by enhancing wild-type p53
We further determined the effects of dsP53-285 trans-
fection on the expression of down-stream genes associ-
ated with cell cycle and mitotic checkpoint in bladder
cancer cells. As shown in Fig. 4a, transfection of dsP53-
285 caused a significant decrease of mRNA levels of
Cyclin D1 and CDK4/6 in both tested cell lines. The
suppressing effects on protein levels of these genes were
further identified by western blotting analysis (Fig. 4b).
Moreover, some essential genes related to the EMT
process were also detected post dsP53-285 transfection.
As seen from Fig. 4c, compared to dsControl group,
dsP53-285 significantly up-regulated the mRNA expres-
sion of epithelial markers, E-cadherin and β-catenin, and
down-regulated mesenchymal markers, ZEB1 and
Vimentin in both cell lines, respectively. Immunoblot
analysis also revealed a robust increase in E-cadherin
and β-catenin, and decrease in ZEB1 and Vimentin pro-
tein levels of the two cell lines after dsP53-285 transfec-
tion (Fig. 4d).
Next, we blocked wild-type p53 expression and exam-
ined the key genes associated with cell cycle. As shown
in Figure Additional file 2: Figure S3C, dsP53-285 failed
to down-regulated Cyclin D1 and CDK4/6 mRNA levels
after siP53 co-transfection. The protein analysis of
immunoblot further proved that (Additional file 2:
Figure S3D). We next assessed the expression levels of
the specific genes mediated EMT process after siP53
transfection. Compared to dsP53-285 group, the mRNA
of epithelial markers (E-cadherin and β-catenin) was
downregulated, whereas mesenchymal markers (ZEB1
and Vimentin) was upregulated after co-treatment of
siP53 for 72 h in both T24 and EJ cells (Additional file 2:
Figure S3E). Additionally, immunoblot analysis further
confirmed that (Additional file 2: Figure S3F). Taken to-
gether, our data strongly imply that dsP53-285 modu-
lates bladder cancer cells cell cycle and EMT associated
genes largely depended on modulating wild-type p53
expression.
Discussion
In the present study, we identified a synthetic dsRNA
(dsP53-285) exhibited considerable potency to activate
wild-type p53 expression by targeting promoter in
Fig. 4 dsP53-285 inhibits Cyclin D1 and CDKs, and reversed EMT-associated genes expression. T24 and EJ cells were transfected with 50 nM of
the indicated dsRNAs for 72 h. a Expression of Cyclin D1 and CDK4/6 mRNA was detected by real-time PCR. GAPDH served as a loading control.
b Expression of Cyclin D1 and CDK4/6 protein was detected by Western blot. α-tubulin served as a loading control. c Expression of EMT-
associated genes mRNA was detected by real-time PCR. GAPDH served as a loading control. d Expression of EMT-associated genes protein was
detected by Western blot analysis. GAPDH served as a loading control. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to dsControl group
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human bladder cancer T24 and EJ cells. Moreover, trans-
fection of dsP53-285 induced the cells cycle arrest, im-
peded growth, migration and invasion. Besides, dsP53-285
could also significantly suppress the growth of bladder
cancer xenografts and metastasis in nude mice. Several
critical Cyclin-CDK genes (Cyclin D1 and CDK4/6) were
down-regulated following transfection. And the EMT-
associated genes (E-cadherin, β-catenin, ZEB1 and Vimen-
tin) were also inversely expressed after dsP53-285 treat-
ment. Most importantly, dsP53-285 inhibited bladder
cancer cells growth and metastasis in vitro and in vivo
mainly via manipulating wild-type p53 expression.
The activating effect of dsP53-285 molecules on p53
gene by targeting its promoter was initially discovered in
African green monkey (COS1) and chimpanzee (WES)
cells. Besides, dsP53-285 mediated up-regulation of p53
is conserved in mammalian cells [12]. Therefore,
non-human primate disease models may have promising
clinical application for validating dsP53-285-based
bladder cancer therapeutics.
It is important to point out that the kinetics of RNAa
is different from traditional RNA interference. The acti-
vation emerges at approximate 48 h and the expressing
level of targeted gene continues to increase by 72 h
following transfection of specific dsRNA, and lasts for
almost 2 weeks [16, 17]. Our finding also showed that
p53 expression mediated by dsP53-285 presented a
time-course effect. These unique features of RNAa have
been attributed to its nuclear nature and consequent
epigenetic changes at targeted promoters [10, 11, 16].
Consistent with previous studies, we examined the p53
expression at 72 h post dsP53-285 transfection [18, 19].
What is more, this gene positively regulated phenomenon
presents in a dose-dependent manner [10, 20]. So accord-
ing to other reports [21, 22], we transfected the indi-
cated dsRNAs at a final concentration of 50 nM in
our research.
It is disappointed that the exact mechanism of RNAa
remains largely unclear [23, 24]. So far, selecting proper
dsRNA target sites within specific gene promoter is still
a hit-or-miss process [11]. Hence, further studies are
needed to improve the target prediction and facilitate to
elicit preferable RNAa. In present study, we focus on
exploring whether dsP53-285 possessed the ability to
stimulate wild-type p53 expression in human bladder
cancer cells other than non-human primates’ cells.
The p53 is a well-characterized tumor suppressor,
encoded by the TP53 gene located on chromosome
17p13.1 [25, 26]. Analysis of somatic DNA alterations of a
recent study showed that nearly half of high-grade muscle-
invasive bladder cancers had TP53 mutations and TP53
function was inactivated in 76 % patients [6]. In addition,
mutations of TP53 affect one allele, followed by the loss of
the wild-type allele, finally disables the function of p53
completely [27, 28]. Thus, reactivation or up-regulation of
wild-type p53 would undoubtedly contribute to bladder
cancer suppression. Accordingly, our findings strongly ar-
gued transfection of dsP53-285 into bladder cancer cells
could inhibit their proliferation and metastasis through en-
hancing wild-type p53 expression.
Conclusions
Taken together, our study provides evidence that a syn-
thetic dsP53-285 holds potent ability to activate wild-
type p53 expression by targeting complementary motifs
in promoter region of human bladder cancer T24 and EJ
cells. Moreover, dsP53-285 inhibited bladder cancer cells
proliferation and metastasis mainly via regulating p53
expression. Nevertheless, further researches are needed
to clarify the exact RNAa mechanism and expand the
application domain of dsP53-285 in tumor therapeutics.
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Additional file 1: Table S1. Sequences for dsRNAs used in present
study. Table S2. Sequences for real time quantitative PCR primers used in
present study. (DOC 46 kb)
Additional file 2: Figure S3. dsP53-285 inhibits Cyclin D1 and CDKs,
and reversed EMT-associated genes expression mainly by activating
wild-type p53. T24 and EJ cells were transfected with 50 nM of the
indicated dsRNAs for 72 h. (A) Expression of p53 and p21 mRNA levels
was assessed by real-time PCR. GAPDH served as a loading control. (B)
Expression of p53 and p21 protein was detected by Western blot analysis.
GAPDH served as a loading control. (C) Expression of Cyclin D1 and
CDK4/6 mRNA was detected by real-time PCR. GAPDH served as a
loading control. (D) Expression of Cyclin D1 and CDK4/6 protein was
detected by Western blot. α-tubulin served as a loading control. (E)
Expression of EMT-associated genes mRNA was detected by real-time
PCR. GAPDH served as a loading control. (F) Expression of EMT-associated
genes protein was detected by Western blot analysis. GAPDH served as a
loading control. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to
dsP53-285 group. (TIF 4114 kb)
Additional file 3: Figure S1. dsP53-285 suppresses bladder cancer cells
growth largely depended on manipulating wild-type p53 expression. T24
and EJ cells were transfected with 50 nM of the indicated dsRNAs for
72 h. (A) Viable cells were measured from day 1 to 5 following
transfection using the CellTiter 96® AQueous One Solution Cell Proliferation
Assay kit. Results were plotted as OD values. (B) Representative
photographs of colony formation assay. (C) Quantification of the cell
colonies formation. (D) Representative photographs of cell cycle analysis.
(E) Quantification of cell cycle distribution.*P < 0.05 and **P < 0.01
compared to dsP53-285 group. (TIF 7747 kb)
Additional file 4: Figure S2. dsP53-285 inhibits bladder cancer cells
migration and invasion primarily via enhancing wild-type p53. T24 and EJ
cells were transfected with 50 nM of the indicated siP21 and dsRNAs for
72 h. Cell migration and invasion were evaluated after 24 h incubation by
transwell assay. (A) Representative wound healing images were pictured
at 0, 12 and 24 h. (B) The relative distances between wound edges of
bladder cancer cells at 0, 12 and 24 h. (C) Representative photographs of
transwell assay (×200). (D) Number of migrated and invaded cells were
quantified in 5 random images from each treatment group. Results are
plotted as percent (%) relative to dsControl group. *P < 0.05 and **P < 0.01
compared to dsP53-285 group. (TIF 20928 kb)
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